Chemotherapy for metastatic breast cancer

Current Opinion in Obstetrics and Gynecology

Volumn 16, Issue 1, 2004, Pages 37-41

  Biganzoli, Laura ^a   Minisini, Alessandro ^b   Aapro, Matti ^c   Di Leo, Angelo ^a  

^a HOSPITAL OF PRATO   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

^c CLINIQUE DE GENOLIER   (Switzerland)

Author keywords

Breast cancer; Chemotherapy; Metastatic disease; New cytotoxic agents

Indexed keywords

CANFOSFAMIDE; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOCOSAHEXAENOIC ACID; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; EXATECAN; FLUOROURACIL; GLUTATHIONE DERIVATIVE; HEXANOIC ACID DERIVATIVE; IXABEPILONE; METHOTREXATE; MITOMYCIN; MITOXANTRONE; NAVELBINE; ORTATAXEL; PACLITAXEL; PEMETREXED; PREDNISOLONE; RPR 109881A; TAXANE DERIVATIVE; TRASTUZUMAB; UNCLASSIFIED DRUG; VINDESINE;

ANEMIA; ANTINEOPLASTIC ACTIVITY; BREAST CARCINOMA; BREAST METASTASIS; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CYTOTOXICITY; DATA ANALYSIS; DIARRHEA; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; HEADACHE; HUMAN; LOW DRUG DOSE; MEDICAL LITERATURE; MEDLINE; MYALGIA; NAUSEA; NEUTROPENIA; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SENSORY NEUROPATHY; SIDE EFFECT; SKIN DISEASE; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

EID: 1242272137     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001703-200402000-00008     Document Type: Review

References (25)

1. Thomas E, Tabernero J, Fornier M, et al. A phase II study of epothilone analog BMS-247550 in patients (pts) with taxane-resistant metastatic breast cancer (MBC) [abstract]. Proc Am Soc Clin Oncol 2003; 22:10. The epothilone analogs represent an interesting class of drugs in taxane-pretreated patients.
2. Roche HH, Cure H, Bunnell C, et al. A phase II study of epothilone analog BMS-247550 in patients (pts) with metastatic breast cancer (MBC) previously treated with an anthracycline [abstract]. Proc Am Soc Clin Oncol 2003; 22:18.
3. Blum JL, Beveridge R, Robert N, et al. ABI-007 nanoparticle paclitaxel: demonstration of anti-tumor activity in taxane-refractory metastatic breast cancer [abstract]. Proc Am Soc Clin Oncol 2003; 22:17.
4. Johnston RSD, Houston S, Jones A, et al. Efficacy of DHA-paclitaxel (TPX) for the second line treatment of breast cancer [abstract]. Proc Am Soc Clin Oncol 2003; 22:17.
5. Esteva FJ, Rivera E, Cristofanilli M, et al. A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for five days every three weeks to patients with metastatic breast cancer [abstract]. Proc Am Soc Clin Oncol 2003; 22:17.
6. Dieras VC, Limantani SA, Lortholary A, et al. A multicentre, non randomized phase Il study with RPR 109881A in metastatic breast cancer (MBC) patients (pts) [abstract]. Proc Am Soc Clin Oncol 2003; 22:141.
7. Amadori D, Santoro A, Hoffken K, et al. A phase Il trial of a novel taxane BAY 59-8862 in patients with advanced taxane-resistant breast cancer [abstract]. Proc Am Soc Clin Oncol 2003; 22:44.
8. Washington D, Miller K, Budd GT, et al. Phase II study of TLK286 (GST P1-1 activated glutathione analog) as ≥third-line therapy in patients with advanced metastatic breast cancer (MBC) [abstract]. Proc Am Soc Clin Oncol 2003; 22:16.
9. Martin M, Spielmann M, Namer M, et al. Phase II study of pemetrexed in breast cancer patients treated with anthracyclines. Ann Oncol 2003; 14:1246-1252.
10. Freyer G, Delozier T, Lichinister M, et al. Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 2003; 21:35-40. This paper shows that oral vinorelbine is a convenient alternative to the intravenous form.
11. Nabholtz J-M, Falkson C, Campos D, et al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol 2003; 21:968-975. This trial shows how the combination of doxorubicin and docetaxel could represent an interesting alternative to a standard anthracycline-based regimen in patients with good performance status and life-threatening visceral disease.
12. Bontenbal M, Braun JJ, Creemers GJ, et al. Phase III study comparing AT (Adriamycin, Docetaxel) to FAC (Fluorouracil, Adriamycin, Cyclophosphamide) as first-line chemotherapy (CT) in patients with metastatic breast cancer (MBC) [abstract]. Eur J Cancer 2003; 1:S201. This study confirms that the doxorubicin-docetaxel combination is more active than a standard anthracycline-based regimen in terms of response rate and time to progression, at the expense of higher toxicity. The study's survival data should be read with caution.
13. Loesch D, Robert N, Asmar L, et al. Phase II multicenter trial of weekly paclitaxel and carboplatin regimen in patients with advanced breast cancer. J Clin Oncol 2002; 20:3857-3864.
14. O'Shaughnessy J, Nag S, Calderillo-Ruiz G, et al. Gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as first-line treatment for anthracycline-pretreated metastatic breast cancer (MBC): interim results of a global phase III study [abstract]. Proc Am Soc Clin Oncol 2003; 22:7. The addition of gemcitabine to paclitaxel results in increased efficacy. However, paclitaxel every 3 weeks is now questionable as a standard comparator in an anthracycline-pretreated breast cancer population.
15. Ravdin P, Erban J, Overmoyer B, et al. Phase III comparison of docetaxel (D) and paclitaxel (P) in patients with metastatic breast cancer (MBC) [abstract]. Eur J Cancer 2003; 1:S201. This randomized trial shows that full-dose docetaxel is superior to 3-weekly paclitaxel in anthracycline- pretreated breast cancer.
16. Jahanzeb M. Trastuzumab-based combination in metastatic breast cancer: how to make a choice. Clin Breast Cancer 2003; 4:28-38. This is an interesting review on trastuzumab-based combinations in metastatic breast cancer, focusing on the risk/benefit ratio of these regimens.
17. Robert N, Leyland-Jones B, Asmar L, et al. Phase III comparative study of trastuzumab and paclitaxel with and without carboplatin in patients with HER-2/neu positive advanced breast cancer [abstract]. Breast Cancer Res Treat 2002; 76 (Suppl 1):S37. The addition of carboplatin to paclitaxel and trastuzumab results in increased response rate and time to progression.
18. Extra JM, Cognetti F, Chan S, et al. Randomized phase III trial (M77001) of trastuzumab (Herceptin) plus docetaxel versus docetaxel alone, as first-line therapy in patients with HER-2 positive metastatic breast cancer [abstract]. Eur J Cancer 2003; 1:S202. The trastuzumab-docetaxel combination is associated with an interesting response rate, and efficacy when evaluated in parallel with single-agent docetaxel.
19. Burstein HJ, Harris LN, Marcom PK, et al. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 2003; 21:2889-2895.
20. Jahanzeb M, Mortimer JE, Yunus F, et al. Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2+ metastatic breast cancer. Oncologist 2002; 7:410-417.
21. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783-792.
22. Sledge GW, Neuberg D, Bernardo P, et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an Intergroup Trial (E1193). J Clin Oncol 2003; 21:588-592. This is a study that strongly contributes to clarify the relative role of single-agent therapy versus combination therapy for metastatic breast cancer.
23. Heidemann E, Stoeger H, Souchon R, et al. Is first-line single-agent mitoxantrone in the treatment of high-risk metastatic breast cancer patients as effective as combination chemotherapy? No difference in survival but higher quality of life were found in a multicenter randomized trial. Ann Oncol 2002; 13:1717-1729.
24. Soto C, Reyes S, Delgadillo F, et al. Capecitabine (X) plus docetaxel (T) vs capecitabine plus paclitaxel (P) vs sequential capecitabine then taxane in anthracycline pretreated patients (pt) with metastatic breast cancer: early results [abstract]. Proc Am Soc Clin Oncol 2003; 22:10.
25. Nooij MA, de Haes JCJM, Beex LVAM, et al. Continuing chemotherapy or not after the induction treatment in advanced breast cancer patients: clinical outcomes and oncologists' preferences. Eur J Cancer 2003; 39:614-621. The results of this study should be discussed with the patient to decide on treatment duration in patients with non-progressing metastatic breast cancer.